Janeen Noel Doyle, Chief Corporate & Business Development Ofcr at Janux Therapeutics, Inc. (JANX), sold 4,059 shares at $14.03 ($57K) on 2026-06-02, disclosed to the SEC on 2026-06-04.
Open-market sale of $57k JANX by Chief Corporate & Business Development Ofcr. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.